Evaluation of extracellular matrix protein CCN1 as a prognostic factor for glioblastoma

Brain Tumor Pathology

Volumn 32, Issue 4, 2015, Pages 245-252

  Ishida, Joji ^a   Kurozumi, Kazuhiko ^a   Ichikawa, Tomotsugu ^a   Otani, Yoshihiro ^a   Onishi, Manabu ^a   Fujii, Kentaro ^a   Shimazu, Yosuke ^a   Oka, Tetsuo ^a   Shimizu, Toshihiko ^a   Date, Isao ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

CCN1; Glioma; MGMT; Prognostic marker

Indexed keywords

CYSTEINE RICH PROTEIN 61; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; CYR61 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; DISEASE ASSOCIATION; EXTRACELLULAR MATRIX; FEMALE; GLIOBLASTOMA; GROSS TOTAL RESECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; NEUTRON CAPTURE THERAPY; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PARTIAL RESECTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; STEREOTACTIC RADIOSURGERY; SUBTOTAL RESECTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR REMOVAL RATE; WHOLE BRAIN RADIATION THERAPY; AGED; BRAIN NEOPLASMS; GENE EXPRESSION; GENETICS; IMMUNOHISTOCHEMISTRY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; VASCULARIZATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CYSTEINE-RICH PROTEIN 61; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; YOUNG ADULT;

EID: 84945491162     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-015-0227-3     Document Type: Article

References (43)

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
2. Lafuente JV, Alkiza K, Garibi JM et al (2000) Biologic parameters that correlate with the prognosis of human gliomas. Neuropathology 20:176–183
3. Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M (2011) Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol 13:566–579
4. von Deimling A, Korshunov A, Hartmann C (2011) The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 21:74–87
5. Pegg AE (1990) Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50:6119–6129
6. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793–797
7. Brell M, Tortosa A, Verger E et al (2005) Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 11:5167–5174
8. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF (1998) CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci 95:6355–6360
9. O’Brien TP, Yang GP, Sanders L, Lau LF (1990) Expression of cyr61, a growth factor-inducible immediate-early gene. Mol Cell Biol 10:3569–3577
10. Walsh CT, Radeff-Huang J, Matteo R et al (2008) Thrombin receptor and RhoA mediate cell proliferation through integrins and cysteine-rich protein 61. FASEB J 22:4011–4021
11. Holbourn KP, Acharya KR, Perbal B (2008) The CCN family of proteins: structure-function relationships. Trends Biochem Sci 33:461–473
12. Burke E, Grobler M, Elderfield K et al (2013) Double-labelling immunohistochemistry for MGMT and a “cocktail” of non-tumourous elements is a reliable, quick and easy technique for inferring methylation status in glioblastomas and other primary brain tumours. Acta neuropathologica commun 1:22
13. Zhou ZQ, Cao WH, Xie JJ et al (2009) Expression and prognostic significance of THBS1, Cyr61 and CTGF in esophageal squamous cell carcinoma. BMC Cancer 9:291
14. Watari H, Xiong Y, Hassan MK, Sakuragi N (2009) Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype. Gynecol Oncol 112:229–234
15. Tang QL, Chen WL, Tan XY et al (2011) Expression and significance of Cyr61 in distant metastasis cells of human primary salivary adenoid cystic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112:228–236
16. Sabile AA, Arlt MJ, Muff R et al (2012) Cyr61 expression in osteosarcoma indicates poor prognosis and promotes intratibial growth and lung metastasis in mice. J Bone Miner Res 27:58–67
17. Chintalapudi MR, Markiewicz M, Kose N et al (2008) Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL-mutant renal carcinoma cells. Carcinogenesis 29:696–703
18. Esteller M, Toyota M, Sanchez-Cespedes M et al (2000) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 60:2368–2371
19. Lalezari S, Chou AP, Tran A et al (2013) Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol 15:370–381
20. Xie D, Yin D, Wang HJ et al (2004) Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 10:2072–2081
21. Xie D, Miller CW, O’Kelly J et al (2001) Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem 276:14187–14194
22. Xie JJ, Xu LY, Wu ZY et al (2011) Expression of cysteine-rich 61 is correlated with poor prognosis in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol 37:669–674
23. Xie D, Yin D, Tong X et al (2004) Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res 64:1987–1996
24. Chien W, Kumagai T, Miller CW et al (2004) Cyr61 suppresses growth of human endometrial cancer cells. J Biol Chem 279:53087–53096
25. Chen PP, Li WJ, Wang Y et al (2007) Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLOS One 2:e534
26. Maeta N, Osaki M, Shomori K et al (2007) CYR61 downregulation correlates with tumor progression by promoting MMP-7 expression in human gastric carcinoma. Oncology 73:118–126
27. Haseley A, Boone S, Wojton J et al (2012) Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma. Cancer Res 72:1353–1362
28. Miyazaki M, Nishihara H, Terasaka S et al (2014) Immunohistochemical evaluation of O6 -methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma. Neuropathology 34:268–276
29. De Salvo M, Maresca G, D’Agnano I et al (2011) Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells. Int J Radiat Biol 87:518–533
30. Parisi MS, Gazzerro E, Rydziel S, Canalis E (2006) Expression and regulation of CCN genes in murine osteoblasts. Bone 38:671–677
31. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597–602
32. Massague J (2008) A very private TGF-beta receptor embrace. Mol Cell 29:149–150
33. Chahal M, Xu Y, Lesniak D et al (2010) MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncol 12:822–833
34. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115:3–8
35. Bendas G, Borsig L (2012) Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol 2012:676731
36. Pistollato F, Abbadi S, Rampazzo E et al (2010) Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 28:851–862
37. Haque I, Mehta S, Majumder M et al (2011) Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis. Mol Cancer 10:8
38. Kurozumi K, Hardcastle J, Thakur R et al (2008) Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther 16:1382–1391
39. Jun JI, Lau LF (2011) Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov 10:945–963
40. Ishida J, Onishi M, Kurozumi K et al (2014) Integrin inhibitor suppresses bevacizumab-induced glioma invasion. Transl Oncol 7(292–302):e291
41. Shimazu Y, Kurozumi K, Ichikawa T, et al (2015) Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC/Dkk-3 gene therapy for malignant glioma. Gene Ther 22(2):146–154
42. Fujii K, Kurozumi K, Ichikawa T et al (2013) The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus. Cancer Gene Ther 20:437–444
43. Stupp R, Hegi ME, Gorlia T et al (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15:1100–1108